CURRICULUM VITAE

Blood Products Advisory Committee

Ann Butler Zimrin, M.D.

Associate Professor

University of Maryland, Greenebaum Cancer Center

Date May 28, 2008

Personal Information  
Business: 22 South Greene Street , S9D15B
Baltimore, MD 21201
Phone: (410) 328-2594
Fax: (410) 328-6896
Email: azimrin@umm.edu
Personal: ---------------------
----------------------
----------------------
-----------------------
Foreign Languages: ------------------
Education  
------------ Bowdoin College, B.A., Chemistry.
------------ University of Chicago, Pritzker School of Medicine, M.D.
Post Graduate Education and Training 1981-1984 Resident in Internal Medicine,
University of California, San Francisco, CA.
1985-1989 Fellow, Hematology-Oncology,
Hospital of the University of Pennsylvania, Philadelphia, PA.
Certifications Internal Medicine 1987, -------
Medical Oncology 1986, -------
Hematology 1987, ---------
Medical Licensures Maryland, -------------------------
Employment History 1984–1985 Medical Clinic, Kaiser Foundation Hospital, San Francisco, CA.
  1990–1993 Private Practice (parttime), Hematology/Oncology, Towson, MD.
  1989 – 1997 Visiting Scientist, Department of Molecular Biology, American Red Cross, Holland Laboratory, Rockville, MD.
  1998 Private Practice (part-time), Hematology/Oncology, Baltimore, MD.
  1998-2002 La Clinica del Pueblo(part-time) Primary Care, Washington, D.C.
  1999-2002 Staff, Division of Hematology & Medical Oncology, Department of Medicine, Alvin & Lois Lapidus Cancer Institute, Sinai Hospital of Baltimore.
Appointments 2002-2007 Associate Professor, Hematology/Oncology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical System.
  University of Maryland School of Medicine.
Professional Memberships 1990-present American Society of Hematology.
  1998-present American Society of Clinical Oncology.
  2004-present American Association of Blood Banks.
Honors and Awards -------- Phi Beta Kappa.
-------- Phillip Meserve Prize in Chemistry.
-------- Graduation summa cum laude, Bowdoin College.
-------- Graduation with honors from medical school.
Administrative Service  
Institutional
 2003-present Institutional Review Board, University of Maryland Baltimore.
2006-present Vice chair Institutional Review Board, University of Maryland Baltimore.
2005-present Chair, Pharmacy and Therapeutics Committee at the Baltimore Veterans Administration Medical Center
2005-present Representative to the VISN 5 Therapeutic Management Committee.
2005-present Program Director, Hematology/Oncology fellowship program
National
 Steering Committee, Transfusion Medicine and Hemostasis cooperative group.
  American Society of Hematology representative to the American. Association of Blood Banks’ Transfusion Transmitted Diseases Committee
  Committee on Training Programs, American Society of Hematology
Teaching Service 2000-2002 Housestaff instruction during their rotations on the hematology/oncology service at Sinai Hospital.
  2003-present Fellow, medical housestaff, medical student instruction during their rotations on the hematology consult service, UMMS.
  2003-present Fellow, medical housestaff instruction during their oncology consult rotations BVAMC.
  2005 Organization of the medical student Multidisciplinary Oncology elective.
Patents, Inventions and Copyrights  
  #6433138, Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids, issued 8/13/02.

Publications

Journals

  1. Golomb HM, Testa JR, Vardiman JW, Butler AE, Rowley JD. Cytogenetic and ultrastructural features of de novo acute promyelocytic leukemia: The University of Chicago experience (1973-1978). Cancer Genet & Cytogenet 1:69-78, 1979.
  2. Golomb HM, Rowley JD, Vardiman JW, Testa JR, Butler AE. Microgranular acute promyelocytic leukemia: A distinct clinical, ultratructural and cytogenetic entity. Blood 55:253-259, 1980.
  3. Butler AE, Vardiman JW, Golomb HM. Ultrastructural characterization of de novo and secondary leukemias. Virchows Archiv (Cell Pathol) 39:239-257, 1982.
  4. Larson RA, Kondol R, Vardiman JW, Butler AE, Golomb HM, Rowley JR. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. AM J Med 76:827-841, 1984.
  5. Zimrin AB, Eisman R, Vilaire G, Schwarz E, Bennett JS, Poncz M. The structure of platelet glycoprotein IIIa: A common subunit for two different membrane receptors. J Clin Invest 81:1470-1475, 1988.
  6. Zimrin AB, Gidwitz S, Lord S, Schwatz E, Bennett JS, Poncz M. The genomic organization of platelet glycoprotein IIIa. J Biol Chem 265:8590-8595, 1990.
  7. Maciag T, Zhan W, Garfinkel S, Friedman S, Prodovsky I, Jackson A, Wessendorf J, Hu X, Gamble S, Shi J, Brown S, Tarantini F, Zimrin A. Novel mechanisms of fibroblast growth factor I function. Hormone Res 49:105-123, 1994.
  8. Zimrin AB, Villeponteau B, Maciag T. Models of in vitro angiogenesis: Endothelial cell differentiation on fibrin but not matrigel is transcriptionally dependent. Biochem Biophys Res Commun 213:630-638, 1995.
  9. Zimrin AB, Maciag T. Progress towards a unifying hypothesis for angiogenesis. J Clin Invest 97:1359, 1996.
  10. Zimrin AB, Pepper MS, McMahon GA, Nguyen F, Montesano R, Maciag T. An antisense oligonucleotide to the Notch ligand Jagged enhances fibroblast growth factor-induced angiogenesis in vitro. J Biol Chem 271:32499-32502, 1997.
  11. Hla T, Zimrin AB, Evans M, Ballas K, Maciag T. The immediate-early gene product MAD-3/EDG-3lkBa is an endogenous modulator of fibroblast factor-I dependent human endothelial cell growth. FEBS Letters 414:419-424, 1997.
  12. Zimrin AB, Dutton RP, McCunn M, Hess JR. Management of postinjury coagulopathy. TATM 2005;6:37-41.
  13. Badros A, Porter N, and Zimrin A: Bevacizumab therapy for POEMS syndrome. Blood 2005;106:1135.
  14. Hess JR, Zimrin AB: Massive blood transfusion for trauma. Curr Opin Hematol 2005:12:488-92.
  15. Zimrin AB, Hess JR: TTP: Going with the evidence. Crit Care Med (accepted for publication).
  16. Chumsri S, Zimrin AB, Gibble JW, Hess JR. Centro-lobular lung edema in probable transfusion- related acute lung injury. Transfusion 2006 (accepted for publication).
  17. Zimrin AB, Hess JR. Throbotic thrombocytopenic purpura: Going with the evidence. Lippincott Williams and Wilkins. Crit Care Med 2006 Vol. 34 No. 8.
  18. Zimrin AB, Hess JR. Planning for pandemic influenza: effect of a pandemic on the supply and demand for blood products in the United States.Transfusion 2007.
  19. Gonzalez-Cuyar LF, Tavora F, Burke AP, Gocke CCD, Zimrin A, Sauk JJ, Zhao XF. Monomorphic post-transplant lymphoproliferative disorder of the tongue. Diagnostic Pathology 2007, 2:49.
  20. Zimrin AB, Hess JR. Blood donors and the challenges in supplying blood products and factor concentrates. Surgery 6, 2007.

Book Chapters

  1. Zimrin AB, Holcomb JB, Hess JR. Hemorrhage control and thrombosis following severe injury. Chap 46 in Kitchens CS, Alving BM, Kestler CM, eds. Consultative Hemostasis and Thrombosis, 2nd Edition. Philadelphia, Saunders, 2006.

Abstracts

  1. Butler AE , Vardiman JW, Golomb HM. Blast crisis of chronic myelocytic leukemia: Ultrastructural features. 37th Ann Proc Electron Microscopy Soc Amer 232, 1979.
  2. Mintz UI, Selhub J, Butler AE, Golomb HM. Vitamin BI2 binding proteins in hairy cell leukemia and other lymphoproliferative disorders. Clin Res 27:301a, 1979.
  3. Butler AE , Golomb HM, Vardiman JW. Ultrastructural classification of leukemias arising as a second malignancy. Clin Res 27, 636a 1979.
  4. Butler AE , Golomb HM, Vardiman JW. Ultrastuctural classification of acute leukemias. Proc Amer Assoc for Cancer Res 21:171a, 1980.
  5. Butler-Zimrin AE , Eisman R, Surrey S, Heidenriech RA, Vilaire G, Schwartz E, Bennett 1M, Poncz M. Isolation and characterization of cDNA clones for the platelet membrane glycoproteins IIb and IIIa. Clin Res 36:597a, 1987.
  6. Zimrin AB , Heidenriech R, Eisman R, Bennett JS, Schwartz E, Poncz M. Isolation and characterization of the genes for human platelet glycoprotein IIib and IIIa. Clin Res 36:571a, 1988.
  7. Zimrin AB, Maciag T. Endothelial cell differentiation on matrigel may not require a transcriptional event. J Cell Biol 111:147a, 1990.
  8. Zimrin AB, Engleka KA, Maciag T. Effect of a pseudomonas toxin-acidic fibroblast growth facto chimera on the growth of A431 cells and BALB 3T3 cells. VIIth International Symposium on the Biology of Vascular Cells.
  9. Zimrin AB, Austin E, Maciag T. Isolation of novel cDNAs from endothelial cells induced to differentiate by plating on fibrin gels. Blood 82 (10, suppl 1):276a, 1993.
  10. Zimrin AB, Pepper MS, Montesano R, Maciag T. An antisense oligonucleotide to the Notch ligand Jagged promtes angiogenesis in bovine microvascular endothelial cells (BMEC) on collagen gels. FASEB J 10(6):A1094, 1996.
  11. Zimrin AB, Wong MKK, Maciag T. Characterization of a soluble Jagged transcript from human endothelial cells. Molec Biol Cell 8:229a, 1997
  12. Lee E, Zamkoff, Gentile TC and Zimrin A. Rituxan in the treatment of auto-immune hemolytic anemia. Blood 960-596a, 2000.
  13. Carter K, Settle K, Taylor R, Wolf J, Kwok Y, Cullen K, Ord R, Zimrin AB, Strome S, Suntharalingam M,. Site as a Prognostic Factor in Patients with Stage III/IV Squamous Cell Carcinoma of the Head and Neck Following Definitive Chemoradiation.

---------------------------------------------------------------

 
Updated: June 5, 2008